DaVita

When researching DaVita, analysts typically begin with its Health Care sector positioning and Health Care Services industry dynamics. DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

The company reports trailing twelve-month revenue of $3.42B and net income of $197.53M. Key metrics include a return on equity of -26.2%, a debt-to-equity ratio of -21.78.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for DVA to support both active traders and long-term investors.